Image Credit: NovoCare Pharmacy

图片出处：NovoCare药房

What You Should Know:

你应该知道的：

–

–

WeightWatchers

体重观察者

, the global leader in science-backed weight management, announced a expansion of its collaboration with

，科学支持的体重管理领域的全球领导者，宣布了与之合作的扩展

Novo Nordisk t

诺和诺德

hat will increase access to authentic, FDA-approved Wegovy® (semaglutide) injection through WeightWatchers Clinic.

这将通过WeightWatchers诊所增加获得正宗的、FDA批准的Wegovy®（司美鲁肽）注射液的机会。

– The collaboration aims to simplify the prescription process, enhance affordability, and explore real-world research initiatives to improve long-term outcomes for individuals managing their weight.

- 该合作旨在简化处方流程、提高可负担性，并探索真实世界的研究计划，以改善管理体重的个人的长期效果。

Streamlined Access and Affordability for Members

会员访问和负担能力的简化

As part of the expanded collaboration, WeightWatchers Clinic members will benefit from a simplified prescription process via

作为扩大合作的一部分，WeightWatchers诊所会员将通过简化处方流程受益。

NovoCare® Pharmacy

诺华关怀®药房

. CenterWell Pharmacy®, a seven-time MMIT Specialty Pharmacy Patient Choice Award winner, will serve as the dispensing pharmacy for the NovoCare® program. This will facilitate direct fulfillment and home delivery of Wegovy® prescriptions for WeightWatchers Clinic members.

CenterWell Pharmacy®，七次获得MMIT专业药房患者选择奖，将作为NovoCare®计划的配药药房。这将促进Wegovy®处方的直接履行和家庭递送，服务于WeightWatchers诊所会员。

In addition to simplified delivery, WeightWatchers will enhance the member experience by providing integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking.

除了简化的交付方式，WeightWatchers 将通过提供集成的账户访问、捆绑定价机会、库存可见性和运输跟踪来提升会员体验。

To further expand access, Novo Nordisk is offering a limited-time savings offer. Starting July 1, 2025, eligible cash-pay members of WeightWatchers Clinic can access Wegovy® at a reduced price of $299 until July 31, 2025. This significant saving is aimed at broadening access to clinically validated, FDA-regulated treatment options..

为了进一步扩大获取渠道，诺和诺德公司提供了一项限时优惠。自2025年7月1日起，符合条件的WeightWatchers诊所现金支付会员可以以299美元的优惠价格获取Wegovy®，直至2025年7月31日。这一显著的优惠旨在拓宽经临床验证、受FDA监管的治疗选择的获取途径。

Real-World Research and Clinical Impact

现实世界研究与临床影响

WeightWatchers and Novo Nordisk will also explore opportunities for further collaboration on real-world research initiatives and strategies to improve long-term outcomes. The aim is to evaluate the potential impact of combining Wegovy®, the most widely used GLP-1 medication globally, with WeightWatchers’ nutrition and behavioral support program, to demonstrate the clinical and economic value of this integrated care model..

WeightWatchers 和诺和诺德还将探索在真实世界研究计划和改善长期效果策略方面进一步合作的机会。目标是评估将全球最广泛使用的 GLP-1 药物 Wegovy® 与 WeightWatchers 的营养和行为支持计划相结合的潜在影响，以展示这种整合护理模式的临床和经济价值。

Wegovy®, first approved in 2021, is the only FDA-approved semaglutide treatment for weight loss. It transformed obesity treatment as the first weekly GLP-1 for chronic weight management and currently supports nearly 1.5 million patients in the U.S.. In 2024, the FDA expanded Wegovy®’s label to include an indication for reducing the risk of major cardiovascular events in adults with known heart disease and either obesity or overweight..

Wegovy® 于2021年首次获批，是唯一获得FDA批准的用于减肥的司美鲁肽治疗药物。作为首个用于慢性体重管理的每周一次GLP-1药物，它革新了肥胖症的治疗，目前在美国已帮助近150万名患者。2024年，FDA扩大了Wegovy®的适应症标签，新增了降低已知心脏病且肥胖或超重成人心血管主要事件风险的适应症。

Preliminary real-world evidence is promising: a study of 3,260 WeightWatchers Clinic members prescribed a GLP-1 showed participants lost an average of 21% of their body weight at 12 months, indicating that combining a GLP-1 with WeightWatchers’ holistic support model can deliver superior, sustainable outcomes..

初步的现实世界证据令人鼓舞：一项针对3260名被处方GLP-1的WeightWatchers诊所会员的研究显示，参与者在12个月内平均减掉了21%的体重，这表明将GLP-1与WeightWatchers的全面支持模式相结合可以带来更优、更可持续的效果。

Scott Honken, Chief Commercial Officer at WeightWatchers, stated, “By deepening our collaboration with Novo Nordisk, we are helping more people access the FDA-approved treatment they deserve, delivered within a holistic clinical model proven to support real, sustainable and improved health outcomes”.

WeightWatchers首席商务官Scott Honken表示：“通过加深与诺和诺德的合作，我们正在帮助更多人获得他们应得的FDA批准的治疗，并在一个已被证明能够支持真正、可持续和改善健康结果的整体临床模式中进行交付。”

He emphasized that WeightWatchers “remains the trusted leader, bringing together access to safe, FDA-approved medication and best-in-class lifestyle support, setting the bar for the gold standard of responsible weight management”..

他强调，WeightWatchers“仍然是值得信赖的领导者，将安全的、FDA批准的药物与一流的生活方式支持相结合，为负责任的体重管理树立了黄金标准”。